LB1410

DRUG3 trials

Sponsors

L & L Bio Co., Ltd., Ningbo, China

Conditions

Cervical CancerLymphomaSolid Tumor

Phase 1

A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）

RecruitingNCT05357651

L & L Bio Co., Ltd., Ningbo, ChinaLymphoma, Solid Tumor

Start: 2022-08-12End: 2028-12-30Target: 100Updated: 2025-09-11

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

RecruitingNCT06468358

L & L Bio Co., Ltd., Ningbo, ChinaSolid Tumor

Start: 2024-06-19End: 2027-12-30Target: 194Updated: 2025-09-11

Phase 2

Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

Not yet recruitingNCT07177716

L & L Bio Co., Ltd., Ningbo, ChinaCervical Cancer

Start: 2025-10-31End: 2028-12-31Target: 120Updated: 2025-09-17

Related Papers

Phase I/II study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in combination with LB4330, a long-acting IL-10, in patients with advanced solid tumors.

Journal of Clinical Oncology2026-05-27

Phase I study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors.

Journal of Clinical Oncology2026-05-27

Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.

Journal of Clinical Oncology2025-05-28

Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-011 citations

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS

Antibody Therapeutics2023-07-01

Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.

Journal of Clinical Oncology2023-06-012 citations